Clinical Trial Update: A Study of Bendamustine in the Treatment of Chinese Participants With Indolent Non-Hodgkin Lymphoma Refractory to Rituximab Treatment [Phase 3]

View source ↗

Summary

A Phase 3 trial evaluating bendamustine in Chinese patients with rituximab-refractory indolent non-Hodgkin lymphoma has completed with results posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-hodgkin Lymphoma

Drugs mentioned

• Bendamustine (Bendamustine)

Snippet

Sponsor: Teva Branded Pharmaceutical Products R&D, Inc. | Conditions: Non-Hodgkin Lymphoma | Phase 3 | Status: COMPLETED | Results posted: 2023-05-26